Nanocarrier vaccines for SARS-CoV-2

• DOI: 10.1016/j.addr.2021.01.002
• Publication Date: 2021-01-11T12:48:07Z
• Authors: Jatin Machhi; Farah Shahjin; Srijanee Das; Milankumar Patel; Mai Mohamed Abdel...; Jacob D. Cohen; Preet Amol Singh; Ashish Baldi; Neha Bajwa; Raj Kumar; Lalit K. Vora; Tapan A. Patel; Maxim D. Oleynikov; Dhruvkumar Soni; Pravin Yeapuri; Insiya Mukadam; Rajashree Chakrab...; Caroline G. Saksena; Jonathan Herskovitz; Mahmudul Hasan; David Oupicky; Suvarthi Das; Ryan F. Donnelly; Kenneth S. Hettie; Linda Chang; Howard E. Gendelman; Bhavesh D. Kevadiya
• Keywords: 0301 basic medicine; Drug Carriers; COVID-19 Vaccines; SARS-CoV-2; 610; Pharmaceutical Science; COVID-19; Viral Vaccines; Article; name=SDG 3 - Good Health and Well-being; 3. Good health; 03 medical and health sciences; Drug Delivery Systems; Nanocapsules; 616; /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being; Animals; Humans; /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being; name=SDG 3 - Good Health and Well-being

The SARS-CoV-2 global pandemic has seen rapid spread, disease morbidities and death associated with substantive social, economic and societal impacts. Treatments rely on re-purposed antivirals and immune modulatory agents focusing on attenuating the acute respiratory distress syndrome. No curative therapies exist. Vaccines remain the best hope for disease control and the principal global effort to end the pandemic. Herein, we summarize those developments with a focus on the role played by nanocarrier delivery.